Hemostasis Pulse

Should we shift away from unselective screening panels and test only whenresults directly alter clinical management?This episode of Hemostasis Pulse highlights high-yieldclinical indications—such as atypical site thrombosis and targeted familyscreening—while emphasizing the critical timing of evaluation.For laboratory specialists, we break down DOAC analytical interferencesand practical neutralization strategies to ensure diagnostic accuracy.Master the diagnostic workflow for Antiphospholipid Syndrome (APS)using the sequential screening–mixing–confirmation protocol (dRVVT, APTT-LA)aligned with ISTH guidelines.Avoid diagnostic pitfalls by clearly differentiating transient acquireddrops from true inherited deficiencies (Antithrombin, Protein C, and ProteinS).Tunein to this 40-minute expert discussion

Discover why traditional aPTT falls short and how Anti-Xa assay selection directly impacts patient safety, strictly aligned with ISTH, BSH, SFH, SFTH, and ASH guidelines.Uncover the clinical risk of dextran sulfate additives causing false residual heparin results after protamine reversal, alongside vital pre-analytical rules to avoid PF4 interference.Join our expert discussion featuring Bruno Pougault (Global International Hemostasis Product Manager) to master reagent quality and optimize antithrombotic monitoring!

Descubra por qué el TPPA resulta insuficiente y cómo la calidad del ensayo Anti-Xa transforma la seguridad del paciente, según las recomendaciones de ISTH, BSH, SFH, SFTH y ASH.Analizamos el peligro del sulfato de dextrano en la sobreestimación de heparina tras la neutralización por protamina y las claves preanalíticas para evitar el sesgo por PF4.¡Acompáñenos en esta discusión junto a Bruno Pougault (Global International Hemostasis Product Manager) para elevar la precisión analítica de su laboratorio!

For World Thrombosis Day 26, this Hemostasis Pulse podcast explores whylupus anticoagulant testing remains one of the most challenging areas ofhemostasis laboratory medicine.The episode reviews patient selection, preanalytical requirements,complementary dRVVT and LA-sensitive aPTT pathways, mixing and confirmatoryprocedures, anticoagulant interference, persistent positivity, and diagnosticdelay in antiphospholipid syndrome.The episode also examines whether clinically relevant lupus anticoagulantand antiphospholipid syndrome may be under-recognized. Current evidencesupports concern about diagnostic delay and misclassification, but noscientifically validated global percentage of undiagnosed lupus anticoagulantis available.Intended for healthcare and laboratory professionals. This contentprovides scientific education and does not replace clinical judgment, localrecommendations, or product instructions for use.

D-Dimer is a cornerstone of emergency medicine andcardiovascular diagnostics, yet assay variability and reporting unitdiscrepancies continue to cause significant clinical interpretation challenges.

Nos vemos el Viernes 9 de Octubre en el Congreso COLABIOCLI 2026, en Santa Cruz de la Sierra, Bolivia . ¡No dejes que tu laboratorio opere a ciegas bajo la sombra de la variabilidad analítica! Ven a poner el Dímero D bajo la lupa.

Le D-Dimère est un biomarqueur très fiable dans de nombreux cas. comme par exemple la maladie thromboembolique ou la coagulation intravasculaire disséminée.Aujourd’hui, la réalité est que toutes les analyses ne sont pas identiques.La controverse et la confusion existent parfois.Nous abordons l’importance du choix du réactif, enfin, nous concluons avec la pertinence clinique dudimère D